When CVS made the decision to forego tobacco sales, the estimated $2 billion in annual revenues it gave up amounts to more than twice the amount of money ACS collects in a year (The Cancer Letter, Feb. 7). However, ACS positions itself as the vanguard of tobacco control, and critics say that close association with a retailer that profits from tobacco undermines the society’s own goals and harms its brand.
Speaking on The Cancer Letter Podcast, Taofeek Kunle Owonikoko recalled recent conversations with two junior faculty members at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
